<DOC>
	<DOCNO>NCT00608946</DOCNO>
	<brief_summary>The efficacy 8 mg copper daily regard cognitive function , content beta amyloid protein CSF volumetric change brain examine first double-blind , placebo-controlled human clinical trial conduct 70 patient mild Alzheimer´s dementia .</brief_summary>
	<brief_title>Treatment With Copper Patients With Mild Alzheimer´s Dementia</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Copper</mesh_term>
	<criteria>male female patient 50 80 year criteria mild dementia probable Alzheimer´s dementia accord NINCDSADRDA criterion give write informed consent relative fill questionnaire ; caregiver consent free serious unstable somatic illness unable give inform consent unable take cholinesterase inhibitor unapproved medication moderate severe Alzheimer´s disease dementia etiology history alcohol , drug medication abuse psychiatric disorder , e. g. schizophrenia know copper zinc storage disease know copper zinc intolerance vegan know severe allergy intolerance insufficient knowledge German language female patient childbearing potential , pregnant nursing patient participation clinical trial within past 30 day onset study severe somatic disease high mortality rate AST , ALT , GGT , GLDH , AP bilirubin twofold normal range</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>January 2008</verification_date>
	<keyword>efficacy treatment copper patient mild Alzheimer´s disease</keyword>
	<keyword>cognitive status time</keyword>
	<keyword>CSF volumetric data time ( 1 year )</keyword>
</DOC>